Tupotilov O. V., Kolyada T. I.


About the author:

Tupotilov O. V., Kolyada T. I.



Type of article:

Scentific article


Peripheral monocytes play an important role in all stages of the development of multiple sclerosis (MS), in particular they are involved in the formation of a pro-inflammatory context on both sides of the bloodbrain barrier, and also have a wide range of immunoregulatory functions. Analysis of the ability of peripheral blood monocytes to activate when stimulated by TLR4 and TLR7/8, including the features of cytokinogenesis, is important for characterizing changes in the functional state of these cells, understanding their pathogenetic role in RRMS and progressive types (PMS) of disease. 48 patients with MS and 27 practically healthy persons (control group) were examined in this study. The in vitro experiment included the isolation of peripheral blood monocytes and their cultivation in three parallel series: intact cells; with the addition of the TLR4 stimulator; with the addition of the TLR7/8 stimulator. Peripheral blood monocytes were isolated on a double percoll gradient and resuspended with a complete RPMI medium supplemented with 1 μg/ml LPS E. Coli or ssRNA40/LyoVec (Invivogen, USA) until the final cell concentration in the wells of the plate reached 1×105 cell/ml and the final volume reached 0.2 ml, and then were incubated in 96-well plates for 24 hours at t=37 °C under 5% CO2 atmosphere. The assay of TNF-α, IL-1β, IL-1RA, IL-6, IL-10, IL-12 in culture supernatants was performed by ELISA. For each experimental series, the IL-1RA/IL-1β ratio was calculated. For the LPS and ssRNA40/LyoVec series, the reserve capacity index (RCi) of monocytes was calculated as the ratio of the production of each of the cytokines in the series with the addition of the appropriate stimulator and the series with intact cells. Results. It was found a decrease in the ratio of spontaneous production of IL-1RA and IL-1β and an increased RCi for LPS- and ssRNA-induced production of IL-6 against a background of decreased RCi for production of TNF-α, IL-1β and IL-10 in comparison with healthy persons (p<0.05). The RCi for ssRNA40/LyoVec-induced production of IL-6 and IL-10 was lower, and IL-1RA was higher compared to stimulation with LPS. Peripheral monocytes of patients with relapsing-remitting MS were also characterized by a decreased spontaneous production of IL-12p70 and an increased RCi for LPS- and ssRNA40/LyoVec-induced production of this cytokine. In patients with progressive type of disease, a high level of spontaneous production of IL-12p70 and IL-1RA was found against a background of reduced RCi for stimulated production of IL-12p70. By TLR4-stimulation it was found an increase in level of IL-6, a decrease in RCi for production of IL-1RA and a decrease in a ratio of induced production of IL-1RA and IL-1β, and by TLR7/8 stimulation – an increase in the level of IL-1β (p <0.05). Conclusions. The obtained results demonstrate differences in the state of cytokinogenesis when stimulated by TLR4 and TLR7/8 and may indicate the presence of functional and phenotypic alterations of peripheral blood monocytes, depending on the type of course of the disease.


multiple sclerosis, monocytes, cytokines, Toll-like receptors


  1. Goodin DS, editor. Handbook of Clinical Neurology: Multiple Sclerosis and Related Disorders. Elsevier B.V. 2014;122:736.
  2. Mammana S, Fagone P, Cavalli E, Basile MS, Petralia MC, Nicoletti F, et al. The Role of Macrophages in Neuroinflammatory and Neurodegenerative Pathways of Alzheimer’s Disease, Amyotrophic Lateral Sclerosis, and Multiple Sclerosis: Pathogenetic Cellular Effectors and Potential Therapeutic Targets. International Journal of Molecular Sciences. 2018;19(3):831. Available from: https://doi.org/10.3390/ ijms19030831 (accessed 20 July 2018)
  3. Baufeld C, O’Loughlin E, Calcagno N, Madore C, Butovsky O. Differential contribution of microglia and monocytes in neurodegenerative diseases. J. Neural. Transm. 2018;125(5):809-26. Available from: https://doi.org/10.1007/s00702-017-1795-7 (accessed 21 July 2018)
  4. Iacobaeus E, Douagi I, Jitschin R, Marcusson-Ståhl M, Andrén AT, Gavin C, et al. Phenotypic and functional alterations of myeloid derived suppressor cells during multiple sclerosis disease course. Immunology and Cell Biology. 2018. Available from: https://onlinelibrary.wiley.com/ doi/abs/10.1111/imcb.12042 (accessed 7 July 2018)
  5. Chuluundorj D, Harding SA, Abernethy D, La Flamme AC. Expansion and preferential activation of the CD14(+)CD16(+) monocyte subset during multiple sclerosis. Immunol Cell Biol. 2014;92:509-17. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1038/icb.2014.15 (accessed 15 March 2017)
  6. Boyette LB, Macedo C, Hadi K, Elinoff BD, Walters JT, Ramaswami B, et al. Phenotype, function, and differentiation potential of human monocyte subsets. PLoS ONE. 2017;12(4):e0176460. Available from: https://doi.org/10.1371/journal.pone.0176460 (accessed 22 April 2018)
  7. Wong KL, Yeap WH, Tai JJY, Ong SM, Dang TM, Wong SC. The three human monocyte subsets: implications for health and disease. Immunol. Res. 2012;53:41-57. Available from: https://doi.org/10.1007/s12026-012-8297-3 (accessed 12 May 2018)
  8. Cros J, Cagnard N, Woollard K, Patey N, Zhang SY, Senechal B, et al. Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors. Immunity. 2010;33:375–86. Available from: https://doi.org/10.1016/j.immuni.2010.08.012 (accessed 16 November 2017)
  9. Gooshe M, Abdolghaffari A, Gambuzza M, Rezaei N. The role of Toll-like receptors in multiple sclerosis and possible targeting for therapeutic purposes. Reviews in the Neurosciences. 2014;25(5):713-39. Available from: https://doi.org/10.1515/revneuro-2014-0026 (accessed 1 July 2018)
  10. Miranda-Hernandez S, Baxter AG. Role of toll-like receptors in multiple sclerosis. American journal of clinical and experimental immunology. 2013;2(1):75-93. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3714200/ (accessed 3 September 2016)
  11. Deckx N, Willekens B, Wens I, Eijnde BO, Goossens H, Van Damme P, et al. Altered molecular expression of TLR-signaling pathways affects the steady-state release of IL-12p70 and IFN-a in patients with relapsing-remitting multiple sclerosis. Innate Immunity. 2016;22(4):266-273. Available from: https://doi.org/10.1177/1753425916642615 (accessed 15 August 2017)
  12. Butchi NB, Pourciau S, Du M, Morgan TW, Peterson KE. Analysis of the Neuroinflammatory Response to TLR7 Stimulation in the Brain: Comparison of Multiple TLR7 and/or TLR8 Agonists. J. Immunol. 2008;180(11):7604-12. Available from: https://doi.org/10.4049/ jimmunol.180.11.7604 (accessed 4 July 2018)
  13. Johnson TP, Tyagi R, Patel K, Schiess N, Calabresi PA, Nath A. Impaired toll-like receptor 8 signaling in multiple sclerosis. Journal of Neuroinflammation. 2013;10:74. Available from: https://doi.org/10.1186/1742-2094-10-74 (accessed 7 July 2018)
  14. Ka MB, Olive D, Mege JL. Modulation of monocyte subsets in infectious diseases. World J Immunol 2014;4(3):185-93. Available from: http:// doi.org/10.5411/wji.v4.i3.185 (accessed 12 May 2018)
  15. Kong BS, Kim Y, Kim GY, Hyun J, Kim S, Jeong A, et al. Increased frequency of IL-6-producing non-classical monocytes in neuromyelitis optica spectrum disorder. Journal of Neuroinflammation. 2017;14:191. Available from: https://doi.org/10.1186/s12974-017-0961-z (accessed 7 July 2018)
  16. Ireland SJ, Monson NL, Davis LS. Seeking Balance: Potentiation and Inhibition of Multiple Sclerosis Autoimmune Responses by IL-6 and IL-10. Cytokine. 2015;73(2):236-44. Available from: https://doi.org/10.1016/j.cyto.2015.01.009 (accessed 9 July 2018)
  17. Burger D, Molnarfi N, Weber MS, Brandt KJ, Benkhoucha M, Gruaz L, et al. Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1β in human monocytes and multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America. 2009;106(11):4355-9. Available from: https://doi.org/10.1073/pnas.0812183106 (accessed 20 April 2018)
  18.  Kallaur AP, Oliveira SR, Simão ANC, Alfieri DF, Flauzino T, Lopes J, et al. Cytokine Profile in Patients with Progressive Multiple Sclerosis and Its Association with Disease Progression and Disability. Mol. Neurobiol. 2017;54(4):2950-60. Available from: https://doi.org/10.1007/s12035016-9846-x (accessed 2 April 2018)
  19. Lin C, Edelson BT. New Insights into the Role of IL-1β in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis. J. Immunol. 2017;198(12):4553-60. Available from: https://doi.org/10.4049/jimmunol.1700263 (accessed 5 May 2018)
  20. Farrokhi M, Etemadifar M, Jafary Alavi MS, Zarkesh-Esfahani SH, Behjati M, Rezaei A, et al. TNF-alpha Production by Peripheral Blood Monocytes in Multiple Sclerosis Patients and Healthy Controls. Immunol Invest. 2015;44:590-601. Available from: https://doi.org/10.3109/0 8820139.2015.1059851 (accessed 14 May 2016)
  21. Fiedler SE, George JD, Love HN, Kim E, Spain R, Bourdette D, et al. Analysis of IL-6, IL-1β and TNF-α production in monocytes isolated from multiple sclerosis patients treated with disease modifying drugs. Journal of systems and integrative neuroscience. 2017;3(3). Available from: https://doi.org/10.15761/JSIN.1000166 (accessed 7 July 2018)
  22. Repnik U, Knezevic M, Jeras M. Simple and cost-effective isolation of monocytes from buffy coats. J. Immunol. Methods. 2003;278(1-2):28392. Available from: https://doi.org/10.1016/s0022-1759(03)00231-x (accessed 12 May 2018)
  23. Belge KU, Dayyani F, Horelt A, Siedlar M, Frankenberger M, Frankenberger B, et al. The proinflammatory CD14+CD16+DR++ monocytes are a major source of TNF. J. Immunol. 2002;168:3536-42. Available from: http://www.jimmunol.org/content/168/7/3536.long (accessed 4 April 2016)
  24. Rossol M, Kraus S, Pierer M, Baerwald C, Wagner U. The CD14(bright)CD16+ monocyte subset is expanded in rheumatoid arthritis and promotes Th17 expansion. Arthritis Rheum. 2012;64:671-7. Available from: https://doi.org/10.1002/art.33418 (accessed 10 June 2016)
  25. Frisdal E, Lesnik P, Olivier M, Robillard P, Chapman MJ, Huby T, et al. Interleukin-6 protects human macrophages from cellular cholesterol accumulation and attenuates the proinflammatory response. J. Biol. Chem. 2011;286:30926-36. Available from: https://doi.org/10.1074/jbc. M111.264325 (accessed 28 August 2017)
  26. Janssens K, Slaets H, Hellings N. Immunomodulatory properties of the IL-6 cytokine family in multiple sclerosis. Ann. N. Y. Acad. Sci. 2015;1351:52-60.
  27. Fernando MR, Reyes JL, Iannuzzi J, Leung G, McKay DM. The proinflammatory cytokine, interleukin-6, enhances the polarization of alternatively activated macrophages. PLoS One. 2014;9:e94188. Available from: https://doi.org/10.1371/journal.pone.0094188 (accessed 12 December 2017)
  28. Smedman C, Ernemar T, Gudmundsdotter L, Gille-Johnson P, Somell A, Nihlmark K, et al. FluoroSpot analysis of TLR-activated monocytes reveals several distinct cytokine secreting subpopulations. Scand. J. Immunol. 2012;75:249-58. Available from: https://doi.org/10.1111/ j.1365-3083.2011.02641.x (accessed 14 December 2017)
  29. Skrzeczynska-Moncznik J, Bzowska M, Loseke S, Grage-Griebenow E, Zembala M, Pryjma J. Peripheral blood CD14high CD16+ monocytes are main producers of IL-10. Scand. J. Immunol. 2008;67:152-9. Available from: https://doi.org/10.1111/j.1365-3083.2007.02051.x (accessed 12 December 2017)

Publication of the article:

«Bulletin of problems biology and medicine» Issue 3 (145), 2018 year, 181-187 pages, index UDK 612.017.11:616.832-004.2